At a recent virtual event, experts discussed the hard tech wave that's coming for Houston. Photo via Getty Images

The past couple decades of innovation has been largely defined by software — and its been a bit of a boom. However, lately it's become evident that it's time for hardware innovation to shine.

At the HX Venture Fund's recent conference, Venture Houston, a few hard tech innovators joined a virtual discussion on the future of hardware — and what Houston's role will be in it.

When it comes to advancing technology for humankind, Adam Sharkawy, founder and managing partner of Boston-based Material Impact, a HXVF portfolio fund, says it's time to expand the walls of what is possible.

"Unlike other types of technologies that may facilitate the possible, deep and hard technologies expand what is in the realm of the possible," he says on the panel. "Software has caught up, and we need a new deep tech wave."

And the future looks promising, as Sharkawy says he's seen hard tech grow over the past 5 to 7 years by about 22 percent. Nic Radford, president and CEO of Houston Mechatronics agrees it's time to shift the focus to hard tech.

"The Information Age was the ubiquitous manipulation of the virtual world, but now we need to uncover the ubiquitous manipulation of the physical world is," he says. "And we need to make those investments toward that."

But investments seem, at least in the recent past, harder to come by for hard tech startups compared to software companies with quick exit strategies.

"Deep tech is traditionally thought of as requiring deep pockets," Sharkawy says.

Radford says there was over $167 billion in capital deployments last year, and only 8 percent of that went to industrial or hard tech. Hardware, he says, is tougher to evaluate, they take longer to exit and are tougher to scale.

"To me that's what makes them a gold mine," Radford adds. "It's an underserved market for sure, and that's because we're tougher to evaluate."

Something to note though, he continues, is that hard tech is going to have a bigger societal impact, but maybe it's not the one with the biggest return.

"I think corporates have an special role to play in the inevitability of hard tech," Radford says. "They aren't completely motivated by financial returns."

Gaurab Chakrabarti, CEO and co-founder of Solugen, says he's had a different experience with raising funds. The Houston entrepreneur has raised over $100 million and is planning to go public soon. He's achieved this by attracting investment from the top VC funds in the country. If you zero in on these powerful funds, you can see they are dedicating more and more funds to this arena. And, he predicts, other VC funds will follow.

"This is a unique time for hardware companies to go and and raise from the top venture capitals of the world," Chakrabarti says.

The city of Houston, with its firm footing in the energy and space industries has an important role to play in this new era.

"The Houston area has all the key ingredients to be an innovation hub — no question," Sharkawy says.

The panelists identified Houston's fine education institutions, major corporations present, access to talent, and more as indicators for success. But the innovation here needs to continue to develop intentionally.

"I'd love to see Houston not try to copycat into a general tech hub," Sharkawy says. "Instead it would be great for Houston leverage its unique position as a leader in energy and space and help its constituents of more traditional energy — big corporates, for example — transform into the new frontier."

Vanessa Wyche, deputy director at NASA's Johnson Space Center, says she's seen the space industry take off as the field becomes more and more commercialized. And locally there's a lot of potential for Houston and all the resources and infrastructure that already exists.

"It's about taking what you're good at, and making it better," she says.

Each of the panelists expressed confidence in this evolving wave of hard tech — and are keeping a close watch on the major players as well as the city of Houston.

"We're going to have to get into the world and do something," Radford says. "That next wave of innovation is specifically interacting with our environment, in my opinion."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.